- Conditions
- Eosinophilic Esophagitis, Eosinophilic Gastrointestinal Disorders (EGIDs)
- Interventions
- 1 Food Elimination Diet, 4 Food Elimination Diet, 4 Food Elimination Diet (post 1FED failure), Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
- Other · Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Eosinophilic Esophagitis
- Interventions
- NDX-3315, NDX-3324, SPECT/CT Imaging
- Drug · Diagnostic Test
- Lead sponsor
- NexEos Diagnostics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Philadelphia, Pennsylvania • Salt Lake City, Utah
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Famotidine, Loratadine, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Observation Period
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Gastroesophageal Reflux Disease (GERD), Eosinophilic Esophagitis (EoE), Functional Dyspepsia
- Interventions
- Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance
- Diagnostic Test
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Diet Change
- Other
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Eosinophilic Esophagitis
- Interventions
- DED, FREE
- Other
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- Wilmington, Delaware • Orlando, Florida • Seattle, Washington
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011, Placebo oral tablet
- Drug
- Lead sponsor
- Ellodi Pharmaceuticals, LP
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts
- Conditions
- Sarcoma
- Interventions
- cyclophosphamide, dexrazoxane hydrochloride, disaccharide tripeptide glycerol dipalmitoyl, doxorubicin hydrochloride, vincristine sulfate, surgical procedure, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 3 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
- Interventions
- etoposide, ifosfamide, intensity-modulated radiation therapy, topotecan hydrochloride, busulfan, melphalan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, autologous bone marrow transplantation
- Drug · Radiation · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 6 Months to 40 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Dysphagia, Eosinophilic Esophagitis
- Interventions
- Esophageal string test
- Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Bone Mineral Density (DEXA) scan, Vitamin D Measurement, Height measurement, Assessment of medication compliance
- Diagnostic Test · Other
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 5 Years to 12 Years
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Reslizumab, Saline
- Biological · Other
- Lead sponsor
- Ception Therapeutics
- Industry
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- barzolvolimab, Matching Placebo
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 20 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Vonoprazan, Placebo
- Drug
- Lead sponsor
- Phathom Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 41
- States / cities
- Little Rock, Arkansas • Chula Vista, California • Los Angeles, California + 35 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- endoflip
- Diagnostic Test
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Baked Milk
- Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- topotecan hydrochloride, vincristine sulfate, cyclophosphamide, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Esophagitis
- Interventions
- esomeprazole, fluticasone
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Eosinophilic Esophagitis
- Interventions
- CC-93538
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
- Conditions
- Barrett's Esophagus, Eosinophilic Esophagitis
- Interventions
- OFDI Capsule
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Plasma and urine metabolomics
- Diagnostic Test
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more
- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis
- Interventions
- AK002, Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 18 more